TORONTO, Nov. 14, 2012 /CNW/ - The Health Research Foundation has
awarded its prestigious Medal of Honour to Dr. Charles Scriver and Mr.
Arnold Steinberg for their outstanding contributions to health sciences
and public health innovation during a ceremony held in Toronto today.
The ceremony was co-hosted with Prix Galien Canada.
"The Health Research Foundation is proud to award the Medal of Honour to
Dr. Charles Scriver and Mr. Arnold Steinberg," said Ms. Teresa Bitetti,
Interim Chair, Rx&D Health Research Foundation and General Manager,
Bristol-Myers Squibb Canada. "Above and beyond their extraordinary
impact on the health of young Canadians, they have both exemplified a
life of dedication to academic medicine."
Together, Dr. Scriver and Mr Steinberg successfully worked to ensure the
addition of vitamin D to milk in Quebec starting in the early 1970s,
reducing the occurrence of nutritional rickets in children from over
1,000 per year to almost none. They have also collaborated on the
development of the National Food Distribution Centre for the Management
of Patients with Hereditary Metabolic Disease. The Centre focusses on
the development of special diets as treatment for children with genetic
disorders, including importing, storage and distribution of specialized
dietary products. Dr. Scriver is a Professor at McGill University and a
world-renowned geneticist and pioneer in the study of genetic diseases
of children, especially resulting from inborn errors of metabolism. Mr
Steinberg is the current Chancellor of McGill University, a
philanthropist and has provided leadership to the Canadian Institutes
of Health Research, the Canadian Patient Safety Initiative, Canada
Health Infoway, and the McGill University Health Centre, to name a few.
The Health Research Foundation co-hosted the award ceremony with Prix
Galien, who awarded the Prix Galien Canada 2012 Research to Dr. Robert
E.W. Hancock, Professor of Microbiology and Immunology at the
University of British Columbia and Canada Research Chair holder. Dr.
Hancock has made major contributions to the area of microbiology and
antimicrobial agents and has shown scientific leadership on many
fronts. He has been involved in the founding of many scientific and
biotechnology organizations and companies. His breakthrough discovery
of a novel way of selectively modulating immunity and suppressing
harmful inflammation while retaining protective immunity has, according
to Prix Galien Canada, the potential to revolutionize human healthcare.
The Prix Galien Canada 2012-Innovative product was awarded to Incivek
(telaprevir) marketed by Vertex Pharmaceuticals Canada Ltd and to
Victrelis (boceprivir) marketed by Merck Canada Inc. Incivek and
Victrelis are the first two direct acting antivirals available in
Canada for the treatment of chronic genotype 1 hepatitis C infection.
The protease inhibitors have been shown to be very effective and appear
to have shortened the duration of the treatment for chronic genotype 1
hepatitis C infection. They represent a significant improvement in the
treatment of the disease and should be considered a real breakthrough.
About the Rx&D Health Research Foundation (HRF)
The Rx&D Health Research Foundation is a non-profit organization whose
mission is to support health research in Canadian academic health
centres and promote the value of health research in Canada. By applying
the highest standards of scientific excellence, addressing health
challenges and establishing partnerships, HRF, one of the leading
private health foundations in the country, contributes significantly to
the prevention and treatment of disease, to a better health care system
and the availability for Canadians to access effective health products.
About Canada's Research-Based Pharmaceutical Companies (Rx&D)
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents the men and women working for more than 50 member companies
which invest more than $1 billion in research and development each year
to fuel Canada's knowledge-based economy, contributing over $3 billion
to the Canadian economy. Guided by our Code of Ethical Practices, our
membership is committed to working in partnership with governments,
healthcare professionals and stakeholders in a highly ethical manner.
About The Prix Galien
The Prix Galien is the most prestigious award in the field of Canadian
pharmaceutical research and innovation. Referred to as the Nobel Prize
of pharmaceutical research, it recognizes the efforts and achievements
of pharmaceutical research and development. The Prix Galien Canada is a
branch of Innovation Life Canada. The mission of Innovation Life Canada
is to celebrate innovators in life sciences through the organization of
events for the general public and most importantly the younger
generations. These events will bring an educational twist by gathering
together the winners of our various awards and distinctions and
affording them the opportunity to share their knowledge and experiences
with the next generation. Innovation Life Canada is a non-profit
SOURCE: CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX&D)
For further information:
For more information on the HRF Medal of Honour:
Telephone: 613-236-0455 (extension 831)
For more information on the Prix Galien: